Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Table 2 Uni- and multivariate analysis (Cox regression, Enter method)

	n	*Univariate*	P-value	*Multivariate* *Enter*	P-value
	n	HR (death) (95% CI)	P-value	HR (death) (95% CI)	P-value
Age^a
< 70	82	0.99 (0.56–1.76)	0.98	0.76 (0.38–1.5)	0.43
≥ 70	27	0.99 (0.56–1.76)	0.98	0.76 (0.38–1.5)	0.43
ECOG^a
0	77	0.46 (0.27–0.77)	0.002	0.68 (0.39–1.19)	0.18
> 0	33	0.46 (0.27–0.77)	0.002	0.68 (0.39–1.19)	0.18
BRAF^a
Mutated	56	0.56 (0.34–0.93)	0.02	0.58 (0.32–1.05)	0.07
Wild type/unknown	53	0.56 (0.34–0.93)	0.02	0.58 (0.32–1.05)	0.07
Number of brain metastases^a
1	47	1.25 (0.85–1.82)	0.29	1.5 (0.425–4.98)	0.30
2–4	52
> 4	10
Extracranial metastases^a
present	82	0.42 (0.56–1.76)	0.02	1.35 (0.37–4.98)	0.65
absent	27	0.42 (0.56–1.76)	0.02	1.35 (0.37–4.98)	0.65
Brain metastases volume
< 1.5 cc	54	0.56 (0.34–0.94)	0.03	0.54 (0.29–0.96)	0.04
≥ 1.5 cc	55	0.56 (0.34–0.94)	0.03	0.54 (0.29–0.96)	0.04
Timing
Synchronous	25	1.84 (1.05–3.24)	0.03	2.43 (1.24–4.75)	0.01
metachronous	84	1.84 (1.05–3.24)	0.03	2.43 (1.24–4.75)	0.01
Systemic therapy
IT	67	1.99 (0.37–8.48)	0.001	3.0 (0.98–9.26)	0.005
IT	34
combination	8
Other metastases controlled
No	38	0.25 (0.01–1.97)	0.001	0.15 (0.01–12.18)	0.78
yes	34
mixed	17
no other metastases	19

Abbreviations: HR Hazard ratio, CI Confidence interval; ^a = factors in the original molGPA score

ISSN: 1748-717X